Physician profile
Samuel R Ruby
NPI 1184626517
$10,068.61
in general payments reported to CMS, 2019-2025
28 companies · $1,392 in 2025
The $1,392 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,276 · 2020: $383 · 2021: $621 · 2022: $334 · 2023: $1,332 · 2024: $1,731 · 2025: $1,392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,438 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,437.58 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,999.36 | 2019-2024 | Xarelto |
| Medtronic Vascular, INC. | $1,971.96 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $957.75 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $857.38 | 2019-2025 | |
| Amgen INC. | $628.67 | 2019-2025 | Repatha, Repatha |
| Amarin Pharma, INC. | $564.96 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $497.51 | 2019-2025 | Eliquis, Camzyos |
| Pfizer INC. | $485.77 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $269.04 | 2021-2025 | Verquvo |
| Novo Nordisk INC | $268.21 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Scpharmaceuticals INC. | $211.69 | 2024-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $156.71 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $148.20 | 2019-2025 | Evkeeza |
| Abiomed | $146.24 | 2023 | Impella |
| Atricure, INC. | $141.54 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $114.10 | 2019-2024 | Lifevest |
| Astellas Pharma US INC | $113.53 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $112.99 | 2019-2024 | |
| Zoll Respicardia, INC. | $74.80 | 2023 | Remede System |
| Bridgebio Pharma, INC. | $68.04 | 2025 | Attruby |
| Esperion Therapeutics, INC. | $66.83 | 2024-2025 | Nexletol |
| Astrazeneca Pharmaceuticals Lp | $64.63 | 2019-2024 | Farxiga |
| Boston Scientific Corporation | $42.39 | 2023 | Watchman Access System, Lux-Dx Insertable Cardiac Monitor |
| Kestra Medical Technology Services, INC. | $40.38 | 2024 | Assure Wcd |
| Kiniksa Pharmaceuticals, Ltd. | $18.21 | 2023 | Arcalyst |
| Heartflow, INC. | $16.77 | 2025 | |
| Inspire Medical Systems, INC. | $15.82 | 2024 | Inspire |
| Glaxosmithkline, LLC. | $15.13 | 2025 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Ruby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.